# Mazdutide

> Mazdutide is a dual GLP-1/glucagon receptor agonist studied primarily in China for obesity and type 2 diabetes. Trials have reported meaningful average body-weight reductions and improvements in glycemic markers. Regulatory status varies by region, and it has not received broad international approval as of current published data. Evidence remains concentrated in specific trial populations, and independent confirmation across broader groups is ongoing.

- URL: https://www.lifeconverted.com/peptides/mazdutide
- Also known as: IBI362, LY3305677
- Primary category: Weight Management
- Effectiveness rank: #4 in Weight Management
- Evidence level: Moderate evidence
- Route: Subcutaneous
- Dose range: 3-9 mg
- Dose tiers: low 3 mg; moderate 6 mg; high 9 mg
- Half-life: Approximately 6 days, consistent with once-weekly dosing
- Timing: Weekly · same day, any time
- Cycle: Continuous use with titration over several months in trial protocols on, Not established outside of trial settings off
- Storage: Refrigerate at 2-8°C; protect from light; do not freeze.

## Mechanism of action

Mazdutide activates GLP-1 receptors, reducing appetite and slowing gastric emptying, while also engaging glucagon receptors, which is thought to increase energy expenditure and support lipid metabolism. This dual mechanism is proposed to complement single-pathway GLP-1 agents by adding an energy-expenditure component.

## Reported benefits

- Associated with meaningful average weight loss in clinical trials
- May improve glycemic control
- Once-weekly dosing schedule
- Dual-pathway mechanism targeting appetite and energy expenditure

## Reported side effects

- Nausea, vomiting, and diarrhea, especially during titration
- Decreased appetite
- Injection-site reactions
- Potential increases in heart rate reported in some trials
- Long-term safety data remain limited outside of studied regions

## Common protocols

- Trial-based step-up titration schedule
- Once-weekly subcutaneous injection with site rotation

## Stacking notes

Not established; combination with other incretin-based agents is not supported by published research.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer